5-BIPHENYL-4-YL-2-METHOXY-[1,3,2]OXAZAPHOSPHOLIDINE 2-SULFIDE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	AASAYAXVIVGERS-UHFFFAOYSA-N
Smiles	COP1(=S)NCC(O1)c2ccc(cc2)c3ccccc3
InChI	InChI=1S/C15H16NO2PS/c1-17-19(20)16-11-15(18-19)14-9-7-13(8-10-14)12-5-3-2-4-6-12/h2-10,15H,11H2,1H3,(H,16,20)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C15H16NO2PS
Molecular Weight	305.33
AlogP	3.04
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	3.0
Polar Surface Area	72.39
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	20.0

Assay Description	Organism	Bioactivity
Insecticidal activity against female Musca domestica (house fly) assessed as mortality compound topically applied to the abdomen measured per fly after 24 hr	Musca domestica	1.0 ug
Insecticidal activity against fourth-instar Tribolium castaneum (red flour beetle) assessed as inhibition of larval weight gain at 30 degC measured after 2 days by feeding method	Tribolium castaneum	62.0 ppm
Insecticidal activity against fourth-instar Tribolium castaneum (red flour beetle) assessed as inhibition of larval weight gain at 30 degC measured per gram of diet after 2 days by feeding method	Tribolium castaneum	203235701.09 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL2289017
PubChem	76327473

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).